Effects comparison of lamivudine therapy for hepatitis B virus genotypes B and C.
- Author:
Jian-liang ZHOU
1
;
Shi-pin WU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antiviral Agents; therapeutic use; DNA, Viral; blood; Female; Gene Products, pol; genetics; Genotype; Hepatitis B virus; classification; genetics; Hepatitis B, Chronic; drug therapy; Humans; Lamivudine; therapeutic use; Male; Mutation
- From: Chinese Journal of Hepatology 2004;12(8):489-490
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo determine the lamivudine response of HBV genotypes in patients with HBV DNA positive chronic hepatitis.
METHODSClinical data from 235 patients in the original trial were analyzed.
RESULTS135 patients received lamivudine and 100 patients as controls. Almost all patients had HBV genotypes B or C. Antiviral response were 92.9% and 75.9% in lamivudine-treated patients (chi-square = 6.628, P < 0.05) and 9.8% and 8.5% in untreated controls (P > 0.05) with HBV genotype B and C, respectively. The incidences of lamivudine-induced mutation in YMDD motif were 3.6% and 16.5% in HBV genotype B and C, respectively (chi-square = 5.508, P < 0.01). We identified HBV genotype B, elevated pretreatment alanine aminotransferase (ALT) levels, and low pretreatment HBV DNA levels as independent factors associated with antiviral response.
CONCLUSIONHBV genotype B was associated with a higher rate of lamivudine-induced HBV DNA clearance and lower rate of lamivudine-induced YMDD mutation compared with genotype C. HBV genotypes may be an important determinant of lamivudine therapy of chronic hepatitis B.
